Alchemab has successfully secured an additional £25 million in funding from the British Business Bank, marking a significant milestone as it represents the largest direct investment in life sciences by the bank to date. This investment aligns with the UK’s strategic efforts to retain high-growth biotech firms within its borders.
Previously, Alchemab raised £60 million in its initial Series A round in 2021, which was intended to propel its initiatives in neurodegeneration and cancer therapies. The company later extended this funding with an additional $32 million after advancing its lead asset, ATLX-1282, into clinical trials.
This latest funding round will bolster Alchemab’s Resiliome platform, which identifies naturally occurring antibodies in individuals with remarkable resilience to difficult diseases. By integrating deep sequencing, AI analysis, and laboratory validation, the company aims to expand its antibody database from 500 million to over one billion sequences, potentially leading to new therapeutic developments.
Despite the promising funding news, the backdrop for UK biotech financing remains challenging, with a reported 49% decline in equity financing in 2025. Major pharmaceutical companies have also scaled back their investment plans in the UK, raising concerns about the future of biotech growth in the region. Alchemab's latest investment not only provides essential resources for its ongoing projects but also underscores the UK’s commitment to addressing funding gaps in the biotech sector.